The effectiveness of treatment of benign oesophageal strictures
resistant to the balloon dilation by biodegradable stents

a 2012

The effectiveness of treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents

ČERNÁ, M; M KÖCHER; Vlastimil VÁLEK; Jiří PÁNEK; Tomáš ANDRAŠINA et al.

Základní údaje

Originální název

The effectiveness of treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents

Autoři

ČERNÁ, M; M KÖCHER; Vlastimil VÁLEK ; Jiří PÁNEK a Tomáš ANDRAŠINA

Vydání

CIRSE 2012, 2012

Další údaje

Typ výsledku

Konferenční abstrakt

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.138

Označené pro přenos do RIV

ISSN

DOI

https://doi.org/10.1007/s00270-012-437-6

Změněno: 31. 10. 2012 13:19, MUDr. Tomáš Andrašina, Ph.D.

Anotace

V originále

Purpose The aim of our study is to present three-year experience in the treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents. Material and Methods From 2007 to 2011 we treated 22 patients (16 men, 6 women, mean age 68.2 years) by 29 biodegradable SX ELLA esophageal stent for benign oesophageal strictures resistant to the balloon dilation. Biodegradable SX ELLA esophageal stent is a self-expandable stent braided from absorbable polydioxanone monofilament. The etiology of stricture was caustic in 2 patients, actinotherapy in 3, postoperative in 7, chronic mycosis in 1 and gastroesophageal reflux disease in 9 patients. Statistical analysis was performed by Kaplan-Meier analysis. Results Stent placement was successful in 21 patients. Technical success was 96.5%. Pain was observed in 2 patients, migration in 2, fistula in one and massive arterial bleeding in one. The mean follow-up was 13.9 months (1-57 months). Primary patency rate was 83.1% (SE: 3.9%), 67.5% (SE: 5%), 58% (SE: 5.9%) a 48.4% (SE: 7.1%) at 6, 12, 24 and 36 months, respectively. Primary patency was 8.7 months, 95% CI: 3.5–13.9 months. Primary-assisted patency (additional effective balloon dilatation) was 12.4 months, 95% CI: 6.4–18.4 months. Conclusion The use of biodegradable SX ELLA esophageal stent is feasible and safe. Its use eliminates the need of removing the stent after long-term dwelling in situ as well as the risk of complications related to the removal. However, mucosal hyperplasia and restenosis are relatively frequent complications.

Citovat

ČERNÁ, M; M KÖCHER; Vlastimil VÁLEK; Jiří PÁNEK a Tomáš ANDRAŠINA. The effectiveness of treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents. In CIRSE 2012. 2012. ISSN 0174-1551. Dostupné z: https://doi.org/10.1007/s00270-012-437-6.

@proceedings{1071444,
   author = {Černá, M and Köcher, M and Válek, Vlastimil and Pánek, Jiří and Andrašina, Tomáš},
   booktitle = {CIRSE 2012},
   doi = {https://doi.org/10.1007/s00270-012-437-6},
   title = {The effectiveness of treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents},
   year = {2012}
}

TY  - CONF
ID  - 1071444
AU  - Černá, M - Köcher, M - Válek, Vlastimil - Pánek, Jiří - Andrašina, Tomáš
PY  - 2012
TI  - The effectiveness of treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents
N2  - Purpose The aim of our study is to present three-year experience in the treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents. Material and Methods From 2007 to 2011 we treated 22 patients (16 men, 6 women, mean age 68.2 years) by 29 biodegradable SX ELLA esophageal stent for benign oesophageal strictures resistant to the balloon dilation. Biodegradable SX ELLA esophageal stent is a self-expandable stent braided from absorbable polydioxanone monofilament. The etiology of stricture was caustic in 2 patients, actinotherapy in 3, postoperative in 7, chronic mycosis in 1 and gastroesophageal reflux disease in 9 patients. Statistical analysis was performed by Kaplan-Meier analysis. Results Stent placement was successful in 21 patients. Technical success was 96.5%. Pain was observed in 2 patients, migration in 2, fistula in one and massive arterial bleeding in one. The mean follow-up was 13.9 months (1-57 months). Primary patency rate was 83.1% (SE: 3.9%), 67.5% (SE: 5%), 58% (SE: 5.9%) a 48.4% (SE: 7.1%) at 6, 12, 24 and 36 months, respectively. Primary patency was 8.7 months, 95% CI: 3.5–13.9 months. Primary-assisted patency (additional effective balloon dilatation) was 12.4 months, 95% CI: 6.4–18.4 months. Conclusion The use of biodegradable SX ELLA esophageal stent is feasible and safe. Its use eliminates the need of removing the stent after long-term dwelling in situ as well as the risk of complications related to the removal. However, mucosal hyperplasia and restenosis are relatively frequent complications.
ER  -

ČERNÁ, M; M KÖCHER; Vlastimil VÁLEK; Jiří PÁNEK a Tomáš ANDRAŠINA. The effectiveness of treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents. In \textit{CIRSE 2012}. 2012. ISSN~0174-1551. Dostupné z: https://doi.org/10.1007/s00270-012-437-6.

Přehled o publikaci